Johnson & Johnson's CEO highlights America's leading role in biopharmaceutical innovation, with U.S. companies driving 55% of global R&D and launching most new medicines. Artificial intelligence is accelerating drug discovery and clinical trials, while also enhancing clinical judgment and surgical precision. The company is investing over $55 billion in U.S. research and manufacturing over the next four years to maintain this leadership and ensure accessibility of treatments. AI
IMPACT AI is accelerating drug discovery and clinical trials, and enhancing clinical judgment and surgical precision in healthcare.
RANK_REASON This is a commentary piece from a CEO discussing industry trends and company investment, not a direct release of a new product or research.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
